The Diabetes Division at UT Health San Antonio is rated as the number one institution in the U.S. for Type 2 Diabetes Mellitus by Expertscape.
Under Dr. DeFronzo’s direction, the Texas Diabetes Institute has been nationally recognized as a top 50 Diabetes Center by U.S. News & World Report.
Our diabetes experts have published their research in international journals, making significant contributions to study and treatment of type 2 diabetes.
UT Health San Antonio conducts clinical research on diabetes through our network of partnerships with the South Texas Veterans Health Care System and the Texas Diabetes Institute.
Dr. Ralph DeFronzo directed the initial studies responsible for the approval of metformin, the number one prescribed medication in the U.S., as well as the development of the most recent class of antidiabetic medications.
A potential cure for Type 1 diabetes looms on the horizon in San Antonio, and the novel approach would also allow Type 2 diabetics to stop insulin shots. The discovery, made at The University of Texas Health Science Center, now called UT Health San Antonio, increases the types of pancreatic cells that secrete insulin.
VeroScience LLC, is pleased to announce that independent research conducted by Dr. Ralph DeFronzo and his team at UT Health San Antonio has continued to delineate metabolic targets of VeroScience’s Cycloset® in reducing hyperglycemia in type 2 diabetes mellitus (T2DM) patients. The study has also identified positive influences of the therapy upon vascular risk factors of cardiovascular disease.
A type 2 diabetes treatment has been found to also have 'off-label' benefits for glucose control in the liver and in fatty cells known as adipose. The study shows that exenatide, a treatment that targets the pancreas to improve glucose absorption, enhances glucose uptake and reduces insulin resistance in the liver and in adipose tissue.